BFRI (Biofrontera) Beginning Cash Position: $6.59 Mil (As of Mar. 2026)


BFRI Biofrontera Inc BFRI
43 GF Score
Price $1.13
GF Value $0.54
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Biofrontera Beginning Cash Position?

Biofrontera BFRI +2.73% 43 Beginning Cash Position is $6.59 Mil as of Mar. 2026. GuruFocus rates BFRI with a GF Score™ of 43/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Biofrontera's Beginning Cash Position for the quarter that ended in Mar. 2026 was $6.59 Mil.

Biofrontera's quarterly Beginning Cash Position declined from Sep. 2025 ($7.44 Mil) to Dec. 2025 ($5.97 Mil) but then increased from Dec. 2025 ($5.97 Mil) to Mar. 2026 ($6.59 Mil).

Biofrontera's annual Beginning Cash Position declined from Dec. 2023 ($17.41 Mil) to Dec. 2024 ($1.54 Mil) but then increased from Dec. 2024 ($1.54 Mil) to Dec. 2025 ($6.11 Mil).

Biofrontera Beginning Cash Position Related Terms

Biofrontera Beginning Cash Position Historical Data

* Premium members only.

The historical data trend for Biofrontera's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofrontera Beginning Cash Position Chart

Biofrontera Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beginning Cash Position
Get a 7-Day Free Trial 8.28 24.74 17.41 1.54 6.11

Biofrontera Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beginning Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.11 10.49 7.44 5.97 6.59
BFRI
43GF Score
Biofrontera Inc BFRI
Beginning Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofrontera Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

What does a Beginning Cash Position of $6.59 Mil mean?
Biofrontera (BFRI) has a Beginning Cash Position of $6.59 Mil as of Mar. 2026. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Biofrontera and its competitors.
Is Biofrontera's Beginning Cash Position too high?
Biofrontera's current Beginning Cash Position is $6.59 Mil. Overall, Biofrontera has a GF Score™ of 43/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera's Beginning Cash Position compare to BIOE and APUS?
Biofrontera's Beginning Cash Position of $6.59 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beginning Cash Position for a Drug Manufacturers company?
A good Beginning Cash Position depends on the Drug Manufacturers industry context. However, Beginning Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beginning Cash Position mean?
A high Beginning Cash Position can signal that a stock is expensive relative to its fundamentals. Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement. View historical data on Biofrontera and its competitors. Biofrontera's current Beginning Cash Position is $6.59 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera (BFRI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $1.13 — trading 109.3% above its estimated fair value. The current Beginning Cash Position is $6.59 Mil. Biofrontera's overall GF Score™ is 43/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beginning Cash Position calculated?
Beginning Cash Position is calculated from a company's financial statements. For Biofrontera (BFRI), the current Beginning Cash Position is $6.59 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofrontera (BFRI) Overvalued in 2026?

Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued. The current stock price of $1.13 is trading 109.3% above its estimated GF Value™ of $0.54. GuruFocus considers Biofrontera to be Significantly Overvalued.

Key valuation signals for BFRI:

  • Beginning Cash Position: $6.59 Mil
  • GF Value™: $0.54 vs. price of $1.13 (109.3% above fair value)
  • GF Score™: 43/100 with 7 warning signs

No single metric tells the full story. See the BFRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofrontera Business Description

Address 660 Main Street, 1st Floor, Woburn, MA, USA, 01801
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
43GF Score

Get the complete analysis for BFRI

Beginning Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.13
Price
$0.54
GF Value